Viking Therapeutics Files 2024 10-K
Ticker: VKTX · Form: 10-K · Filed: Feb 26, 2025 · CIK: 1607678
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
Related Tickers: VKTX
TL;DR
Viking Therapeutics (VKTX) filed its 2024 10-K. Full financials and biz details out.
AI Summary
Viking Therapeutics, Inc. filed its 2024 10-K on February 26, 2025, reporting its fiscal year ending December 31, 2024. The company, operating in pharmaceutical preparations, is based in San Diego, CA. Key financial data and operational details for the fiscal year are presented in this comprehensive annual report.
Why It Matters
This filing provides investors and stakeholders with a detailed overview of Viking Therapeutics' financial health, operational performance, and strategic outlook for the past fiscal year.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Viking Therapeutics is subject to significant risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-02-26 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- Viking Therapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-02-26 (date) — Filing date
- San Diego, CA (location) — Company business address
- 001-37355 (other) — SEC File Number
FAQ
What is Viking Therapeutics' primary business?
Viking Therapeutics, Inc. operates in the Pharmaceutical Preparations industry, as indicated by its SIC code [2834].
When did Viking Therapeutics file its 2024 10-K?
Viking Therapeutics filed its 2024 10-K on February 26, 2025.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Where is Viking Therapeutics located?
Viking Therapeutics' business and mailing address is 9920 Pacific Heights Blvd, Suite 350, San Diego, CA 92121.
What is the SEC file number for Viking Therapeutics?
The SEC file number for Viking Therapeutics is 001-37355.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 26, 2025 regarding Viking Therapeutics, Inc. (VKTX).